ITGAX and neoplasm: The investigators also identified an increasing population of these tolerogenic DCs with metastatic progression and further found that depletion of DCs later in tumor progression using a CD11c-DTR (diphtheria toxin receptor) system impaired tumor growth, suggesting the activation of a phenotypic switch driving DC tolerization during cancer progression (32).